CN114174325A - 用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合 - Google Patents

用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合 Download PDF

Info

Publication number
CN114174325A
CN114174325A CN202080053244.XA CN202080053244A CN114174325A CN 114174325 A CN114174325 A CN 114174325A CN 202080053244 A CN202080053244 A CN 202080053244A CN 114174325 A CN114174325 A CN 114174325A
Authority
CN
China
Prior art keywords
cells
cell
several embodiments
engineered
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080053244.XA
Other languages
English (en)
Chinese (zh)
Inventor
J.B.特雷格
L.G.布伦
C.郭
黎广南
刘道峰
I.陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nkarta Inc
Original Assignee
Nkarta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nkarta Inc filed Critical Nkarta Inc
Publication of CN114174325A publication Critical patent/CN114174325A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
CN202080053244.XA 2019-06-04 2020-06-02 用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合 Pending CN114174325A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962857167P 2019-06-04 2019-06-04
US62/857,167 2019-06-04
US201962943697P 2019-12-04 2019-12-04
US62/943,697 2019-12-04
PCT/US2020/035752 WO2020247392A1 (en) 2019-06-04 2020-06-02 Combinations of engineered natural killer cells and engineered t cells for immunotherapy

Publications (1)

Publication Number Publication Date
CN114174325A true CN114174325A (zh) 2022-03-11

Family

ID=73652681

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080053244.XA Pending CN114174325A (zh) 2019-06-04 2020-06-02 用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合

Country Status (7)

Country Link
US (1) US20220233593A1 (https=)
EP (1) EP3980450A4 (https=)
JP (2) JP7629414B2 (https=)
CN (1) CN114174325A (https=)
AU (1) AU2020288829A1 (https=)
CA (1) CA3140393A1 (https=)
WO (1) WO2020247392A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114774364A (zh) * 2022-04-26 2022-07-22 深圳市体内生物医药科技有限公司 一种嵌合抗原受体t细胞及其制备方法和应用
CN115948341A (zh) * 2022-11-28 2023-04-11 上海恩凯细胞技术有限公司 敲低nkg2a基因的car-免疫细胞及其用途

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
CN110546265A (zh) 2017-02-09 2019-12-06 因达普塔治疗公司 工程化自然杀伤(nk)细胞及其组合物和方法
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR102660336B1 (ko) 2017-03-27 2024-04-26 내셔널 유니버시티 오브 싱가포르 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
CN112055717B (zh) 2018-04-02 2024-04-26 新加坡国立大学 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
US12590148B2 (en) 2018-11-26 2026-03-31 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
WO2021146147A1 (en) * 2020-01-13 2021-07-22 Nkarta, Inc. Bcma-directed cellular immunotherapy compositions and methods
WO2021252804A1 (en) 2020-06-12 2021-12-16 Nkarta, Inc. Genetically modified natural killer cells for cd70-directed cancer immunotherapy
WO2022040577A1 (en) * 2020-08-20 2022-02-24 City Of Hope Compositions and uses of cd45 targeted chimeric antigen receptor modified t cells
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
JP2023552998A (ja) * 2020-12-03 2023-12-20 ンカルタ・インコーポレイテッド 効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
WO2022150392A1 (en) * 2021-01-05 2022-07-14 City Of Hope Natural killer cells engineered to reduce or eliminate cbl-b and uses thereof
EP4305069A4 (en) * 2021-03-08 2025-01-01 University of Pittsburgh - of the Commonwealth System of Higher Education MOLECULES THAT BIND TO CD66E POLYPEPTIDES
US20240197782A1 (en) * 2021-04-20 2024-06-20 Board Of Regents, The University Of Texas System Methods and compositions for genetic modification and therapeutic use of immune cells
WO2022242701A1 (en) * 2021-05-20 2022-11-24 Wuxi Biologics (Shanghai) Co., Ltd. Genetically modified gamma-delta t cells and uses thereof
WO2022242700A1 (en) * 2021-05-20 2022-11-24 Wuxi Biologics (Shanghai) Co., Ltd. Genetically modified nk cells and uses thereof
AU2022301302A1 (en) * 2021-07-01 2024-01-25 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
CN117730094A (zh) * 2021-07-16 2024-03-19 克莱格医学有限公司 用于肿瘤免疫学的组合物和方法
EP4426319A1 (en) * 2021-11-04 2024-09-11 APHP (Assistance Publique - Hôpitaux de Paris) Method for generating nk cells
TW202405165A (zh) * 2022-04-14 2024-02-01 日商第一三共股份有限公司 編碼膜型細胞激素及tnf受體超家族分子之細胞內域的多核苷酸
EP4558152A2 (en) * 2022-07-22 2025-05-28 Board of Regents, The University of Texas System Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105392888A (zh) * 2013-03-16 2016-03-09 诺华股份有限公司 使用人源化抗cd19嵌合抗原受体治疗癌症
WO2018126074A1 (en) * 2016-12-30 2018-07-05 Celularity, Inc. Genetically modified natural killer cells
WO2018183385A1 (en) * 2017-03-27 2018-10-04 National University Of Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
WO2018195339A1 (en) * 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
CN108728459A (zh) * 2017-04-24 2018-11-02 上海恒润达生生物科技有限公司 靶向cd19的嵌合抗原受体并联合表达il-15的方法和用途
CN109153728A (zh) * 2016-03-21 2019-01-04 埃尔斯塔治疗公司 多特异性和多功能分子及其用途
JP2019505498A (ja) * 2015-12-16 2019-02-28 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害
WO2019089884A2 (en) * 2017-11-01 2019-05-09 Editas Medicine, Inc. Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
CN110267982A (zh) * 2016-10-19 2019-09-20 斯克利普斯研究所 具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
CN110724199A (zh) * 2018-07-17 2020-01-24 成都盛世君联生物技术有限公司 Nkg2d car-t细胞及其制备和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7868159B2 (en) * 2005-06-23 2011-01-11 Baylor College Of Medicine Modulation of negative immune regulators and applications for immunotherapy
US20120192298A1 (en) * 2009-07-24 2012-07-26 Sigma Aldrich Co. Llc Method for genome editing
US9487800B2 (en) 2010-09-08 2016-11-08 Chemotherapeutisches Forschunginstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
EP3692794A1 (en) 2011-09-16 2020-08-12 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
MX373460B (es) * 2014-03-11 2020-04-07 Cellectis Metodo para generar celulas t compatibles para el trasplante alogenico.
AU2015259877B2 (en) * 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
AU2015360502A1 (en) * 2014-12-10 2017-06-29 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
CA2976089C (en) * 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
SG11201708516YA (en) * 2015-04-17 2017-11-29 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
KR102438360B1 (ko) * 2016-03-04 2022-08-31 에디타스 메디신, 인코포레이티드 암 면역요법을 위한 crispr-cpf1-관련 방법, 조성물 및 구성성분
EP3519443A4 (en) * 2016-09-30 2020-06-10 Baylor College of Medicine CHIMERIC ANTIGEN RECEPTOR THERAPY WITH REDUCED CYTOTOXICITY FOR VIRAL DISEASE
CA3041831A1 (en) * 2016-10-27 2018-05-03 Intima Bioscience, Inc. Viral methods of making genetically modified cells
US20180100016A1 (en) * 2016-12-22 2018-04-12 Xiaotong Song Use of car-modified human natural killer cells to treat cancer
EP3749770B9 (en) * 2018-02-09 2025-12-17 The U.S.A. as represented by the Secretary, Department of Health and Human Services Tethered interleukin-15 and interleukin-21
MX2020011697A (es) 2018-05-03 2020-12-10 Univ Texas Células exterminadoras naturales diseñadas para expresar receptores de antígeno quimérico con bloqueo de punto de control inmunitario.
WO2020113029A2 (en) * 2018-11-28 2020-06-04 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
EP3924467A1 (en) * 2019-02-15 2021-12-22 Editas Medicine, Inc. Modified natural killer (nk) cells for immunotherapy
AU2020232691B2 (en) * 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
CA3139346A1 (en) * 2019-05-07 2020-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Engineered immune cell targeting bcma and use thereof
MX2022001255A (es) * 2019-07-31 2022-05-10 Nkarta Inc Metodos y composiciones para la expansion y la citotoxicidad mejoradas de las celulas asesinas naturales.
US20220389383A1 (en) * 2019-11-27 2022-12-08 Board Of Regents, The University Of Texas System Large-scale combined car transduction and crispr gene editing of nk cells

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105392888A (zh) * 2013-03-16 2016-03-09 诺华股份有限公司 使用人源化抗cd19嵌合抗原受体治疗癌症
JP2019505498A (ja) * 2015-12-16 2019-02-28 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害
CN109153728A (zh) * 2016-03-21 2019-01-04 埃尔斯塔治疗公司 多特异性和多功能分子及其用途
CN110267982A (zh) * 2016-10-19 2019-09-20 斯克利普斯研究所 具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
WO2018126074A1 (en) * 2016-12-30 2018-07-05 Celularity, Inc. Genetically modified natural killer cells
WO2018183385A1 (en) * 2017-03-27 2018-10-04 National University Of Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
WO2018195339A1 (en) * 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
CN108728459A (zh) * 2017-04-24 2018-11-02 上海恒润达生生物科技有限公司 靶向cd19的嵌合抗原受体并联合表达il-15的方法和用途
WO2019089884A2 (en) * 2017-11-01 2019-05-09 Editas Medicine, Inc. Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
CN110724199A (zh) * 2018-07-17 2020-01-24 成都盛世君联生物技术有限公司 Nkg2d car-t细胞及其制备和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
钱莉: "膜型IL-15联合RAE-1ε增强小鼠NK细胞的杀伤活性", 《中国肿瘤生物治疗杂志》, vol. 18, no. 6, 20 December 2011 (2011-12-20), pages 611 - 616 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114774364A (zh) * 2022-04-26 2022-07-22 深圳市体内生物医药科技有限公司 一种嵌合抗原受体t细胞及其制备方法和应用
CN114774364B (zh) * 2022-04-26 2024-04-26 深圳市体内生物医药科技有限公司 一种嵌合抗原受体t细胞及其制备方法和应用
CN115948341A (zh) * 2022-11-28 2023-04-11 上海恩凯细胞技术有限公司 敲低nkg2a基因的car-免疫细胞及其用途
CN115948341B (zh) * 2022-11-28 2025-05-16 上海恩凯细胞技术有限公司 敲低nkg2a基因的car-免疫细胞及其用途

Also Published As

Publication number Publication date
EP3980450A1 (en) 2022-04-13
JP2025081360A (ja) 2025-05-27
EP3980450A4 (en) 2024-06-19
JP7629414B2 (ja) 2025-02-13
AU2020288829A1 (en) 2021-12-02
JP2022535429A (ja) 2022-08-08
US20220233593A1 (en) 2022-07-28
CA3140393A1 (en) 2020-12-10
WO2020247392A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
CN113766956B (zh) Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
CN114174325A (zh) 用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合
JP7833003B2 (ja) キメラ抗原受容体およびその使用方法
CN115279381A (zh) Bcma定向性细胞免疫疗法组合物和方法
JP2022180471A (ja) 組み合わせがん免疫療法
AU2017355504C1 (en) Anti-BCMA CAR T cell compositions
KR102731379B1 (ko) Bcma 키메릭 항원 수용체
CN112638947B (zh) 用于治疗实体瘤的嵌合抗原受体细胞
HK1244015A1 (zh) 用於癌症和自身免疫疾病的免疫疗法
CN115697387A (zh) 抗bcma嵌合抗原受体的用途
KR20210045985A (ko) 항-bcma 키메라 항원 수용체의 용도
CN110997920A (zh) 新型细胞标签的表达
CN110582299A (zh) 高亲和力mage-a1特异性tcr及其用途
KR20190038825A (ko) 프로그램화된 사멸 1 리간드 1 (pd-l1) 결합 단백질 및 그의 사용 방법
RU2841609C2 (ru) Cd19-направленные химерные антигенные рецепторы и пути их применения в иммунотерапии
KR102461837B1 (ko) Cd80 세포외도메인 및 항 lag3 항체 단편을 포함하는 융합 단백질 및 이의 용도
HK40066121B (zh) Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
HK40066121A (zh) Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
CN116940367A (zh) 工程化改造免疫细胞用于增强的效力和持久性的方法以及工程化细胞在免疫疗法中的用途
CN115397863A (zh) Cd3融合蛋白及其用途
CN117500838A (zh) Ccr4靶向嵌合抗原受体细胞疗法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination